N/A N=507 Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer
Lung Cancer
Primary: Patient-reported Quality of Life — 100.62; 97.75 score on a scale — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=79 Empowering Patients' Lung Cancer Screening Uptake
Lung Cancer
Primary: Order of LDCT — 50 Participants
Phase 1 N=24 Pembrolizumab and Palliative Radiotherapy in Lung
Thoracic Tumours
Primary: Toxicity Rate of Dose Limiting Toxicities (DLTs) Assessed by CTCAEv4 — 0; 0; 0; 0 Participants
Phase 2 N=22 Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy
Non-small Cell Lung Cancer
Primary: Number of Participants With a Change From Baseline in Ventilation Map Using Hyperpolarized Xe-129 MR Imaging — 6 Participants — p=0.041
Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Phase 3 N=72 Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
N/A N=151 Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II
Lung Cancer
Primary: Change From Baseline in Functional Assessment of Cancer Therapy-Lung Total Outcome Index Score at Final Visit — 1.8; -1.2 score on a scale
Phase 2 N=152 Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease
Lung Cancer · Precancerous Condition
Primary: Change in Average (Follow-up - Baseline) From All Biopsies — -0.23; -0.02 WHO Units
N/A N=40 Effectiveness of a Preoperative Pulmonary Rehabilitation Program in Patients Awaiting Lung Resection
Lung Cancer
Primary: Exercise Tolerance — 459.7; 341 Seconds
N/A N=25 Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Lung Cancer
Primary: Number of Red Fluorescent [i.e., Cancer] Cells (RFCs) in Sputum From Healthy Participants — 0 number of RFCs per participant
Phase 2 N=41 Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Define the Maximum Tolerated Dose (MTD) Using This Dose Schedule. — 20; 28.6; 33.3 Percentage subj w dose limiting toxicity
Phase 2 N=40 Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
Lung Non-Small Cell Carcinoma · Stage I Lung Cancer AJCC v8 · Stage IA1 Lung Cancer AJCC v8
Primary: 6-month CT Assessment (Tumor Response Per mRECIST) — 1; 36; 2; 1 Participants
N/A N=90 Lung Cancer Exercise Training Study
Lung Cancer
Primary: Changes in VO2peak (on Exercise Capacity) — 17.9; 15.2; 15.2; 14.5 mL/kg/min
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Phase 2 N=38 Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer
Primary: Overall Survival and Progression Free Survival — 85.70; 60; 42.90; 28.10 percentage of participants (%)
Phase 2 N=71 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Lung Cancer
Primary: Mediastinal Nodal Clearance After Completion of Induction Chemoradiotherapy With or Without Panitumumab. — 68.2; 48.7 percentage of participants — p=0.96
Phase 2 N=128 Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Lung Cancer
Primary: Determine the Clinical Sensitivity and Specificity of the Biomoda CyPath™ Early Lung Cancer Detection Assay Using Sputum Specimens From Two Cohorts of Participants and…
N/A N=40 Supportive Care for Patients Newly Diagnosed With Lung Cancer
Lung Cancer
Primary: Change From Baseline in Functional Assessment of Cancer Therapy-Lung Total Outcome Index Score at 3 Months — 2.7; 4.7 units on a scale
N/A N=781 Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology
Lung Cancer
Primary: Thoroughness of Invasive Staging, Multidisciplinary (MD) vs Serial Care (SC) — 108; 168; 70; 180 Participants — p=0.0007
Phase 2 N=181 Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
Non-Small-Cell Lung Carcinoma
Primary: The Incidence and Time to Development of Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) Grade > 3 Treatment-related Pneumonitis (TRP) — 2; 0…
Early Phase 1 N=21 Bronchoscopic Cryo-Immunotherapy of Lung Cancer
Advanced Non-small Cell Lung Cancer
Primary: Percentage of Successful Performances Among Patients in Whom BCI is Attempted — 100 Percentage of participants
N/A N=7,439 Follow-Up Study for Exubera
Diabetes Mellitus
Primary: Rate of Primary Lung Cancer Mortality — 0.48; 0.17 Deaths per 1000 patient years (PY)
Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
N/A N=53 Piloting Pathways With Lung Cancer Patients
Metastatic Lung Cancer
Primary: Feasibility of Enrollment: Percentage of Eligible and Approached Patients Who Agree to Participate — 53 Participants
Phase 2 N=178 Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease
Lung Cancer Prevention
Primary: Change in Urinary 8-hydroxydeoxyguanosine Levels — 2.36; 5.20; -1.08 ng/mg creatinine
N/A N=215 BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium
Stage IV Non-small Cell Lung Cancer
Primary: The Study Outcome is Defined as the Systemic Treatment Choice. — 26; 68; 0; 99 Participants
N/A N=50 Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer
Lung Neoplasms
Primary: PD-L1 Prevalence IHC — 21; 14; 8; 27 Participants
N/A N=520 Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens
Lung Cancer
Primary: Rate of Moderate to High Arsenic Level in Cases and Controls — 0.04; 0.04 mcg/dL
Phase 2 N=331 Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
Lung Cancer · Small Cell Lung Cancer · Carcinoma, Non-Small-Cell Lung
Primary: Immune-related Progression-free Survival (irPFS) in Participants With Nonsmall-cell Lung Cancer (NSCLC) Per Immune-related Response Criteria (irRC) — 5.52; 5.68; 4.63…
Phase 2 N=18 Trial of NanoPac Intratumoral Injection in Lung Cancer
Lung Cancer, Nonsmall Cell · Lung Cancer · Lung Cancer, Small Cell
Primary: Number of Participants With Treatment Emergent Adverse Events — 18 Participants